Gland Pharma Limited, a small-molecule generic injectables-focused company, announced it has appointed Yao Fang to the company’s Board of Directors, with effect from March 10, 2022. Also, Srinivas Sadu has been re-appointed as Managing Director and Chief Executive Officer, effective March 10, 2022.
According to the company’s exchange filing, “We would like to inform you that the Board of Directors (the “Board”) of Gland Pharma Limited (the “Company”) at its Meeting held today, i.e. Thursday, March 10, 2022 has inter-alia considered and approved the following: 1) Re-appointment of Mr. Srinivas Sadu (DIN: 06900659) as Managing Director and CEO of the Company for a period of 5 years, with effect from 25th April, 2022; subject to the approval of Members of the Company. 2. Appointment of Mr. Yao Fang (DIN: 09524705) as an Additional Director, categorized as Non-Independent and Non-Executive Director, with effect from March 10, 2022 as a Director liable to retire by rotation.”
Yao Fang is the Executive President of Fosun International Limited (listed on the Hong Kong Stock Exchange). He joined the Fosun Group in April 2010 and he is also a Non-Executive Director of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., (listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange).
Prior to joining the Fosun Group, from 1993 to 2009, Yao Fang was successively the Assistant General Manager of the International Business Department of Shanghai Wanguo Securities Company Limited (now known as Shenyin & Wanguo Securities Company Limited), General Manager of Shanghai Industrial Assets Management Company Limited, General Manager of Shanghai Industrial Management (Shanghai) Company Limited, Managing Director of Shanghai Industrial Pharmaceutical Investment Company Limited (a company delisted from the Shanghai Stock Exchange), Chairman of Shanghai Overseas Company, Non-Executive Director of Lianhua Supermarket Holdings Company Limited (a company listed on the Hong Kong Stock Exchange), Executive Director of Shanghai Industrial Holdings Limited (a company listed on the Hong Kong Stock Exchange).
Yao Fang was a Non-Executive Director of BioSino Bio-Technology and Science Incorporation (a company listed on the Hong Kong Stock Exchange) during 2011 to 2014. He obtained a bachelor’s degree in Economics from Fudan University in July, 1989 and a Master’s degree in Business Administration from The Chinese University of Hong Kong in December, 1993.
Srinivas Sadu is the Managing Director and Chief Executive Officer of the Company. He has deep insights and knowledge about the Pharmaceutical Industry and Global Generic Injectable Market. He is instrumental in expanding the business in USA, Europe and the Rest of the World Markets and in establishing world class manufacturing Facilities for the Company, the statement said.
Srinivas Sadu has over 23 years of experience in business development, manufacturing operations, supply chain management and strategic planning. After working with Natco Pharma for a brief stint, he has been associated with Gland Pharma Limited for the last 22 years. He joined the Company as General Manager (Exports) in the year 2000 and later took roles of Senior General Manager (Exports), Vice-President (Exports) and Director (Business Development). He was also the Whole-time Director of the Company from June, 2014 to October, 2017. He was the Chief Operating Officer of the Company from April 30, 2011, to April 25, 2019.
Srinivas Sadu was appointed as the MD and CEO with effect from April 25, 2019 for a period of three years. Under Srinivas Sadu’s leadership, the Company has in the last three years consistently witnessed growth, both in terms of revenue and profits, while expanding across all geographies.
As Gland Pharma’s MD & CEO, Sadu’s priorities have been the Company’s strategic growth, strengthening the Company’s presence in Rest of the World Markets, whilst maintaining its stronghold in USA; expansion of business into newer markets like China and new areas like Biosimilars CDMO; promoting strong relationships with business partners; and strong Business Development.
Sadu holds a Bachelor’s degree in Pharmacy from Gulbarga University; a Master’s degree in Science from Long Island University, New York; and a Master’s degree in Business Administration from University of Baltimore. He also holds a Post Graduate certificate in Finance and Management from the London School of Business and Finance.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.